MedPath

The Effect of Mentholyptus Drops on the Palatability of PEG-Electrolyte Solution

Not Applicable
Completed
Conditions
Colon Cancer
Interventions
Other: PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)
Other: PEG solution (Fortrans®)
Registration Number
NCT01541683
Lead Sponsor
American University of Beirut Medical Center
Brief Summary

The investigators aim is to study the efficacy of mentholyptus drops in improving the palatability of PEG-electrolyte solution used in bowel cleansing for colonoscopy. The study is a randomized controlled trial which will include patients undergoing elective colonoscopy at the American University of Beirut Medical Center. Patients will be randomized into one of two study arms using a computer generated randomization list. Patients assigned to the intervention arm will be asked to have candy (Halls®) during the whole 2 hours period while drinking the PEG solution unlike the control arm patients who will only receive the PEG solution. All patients will then be evaluated for the tolerability of the preparation while taking into account the palatability of the solution as main outcome and the remaining volume of the PEG solution and side effects as secondary outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
99
Inclusion Criteria
  • elective colonoscopy
  • consent to the study
Exclusion Criteria
  • pregnant or lactating women
  • age less than 18 years
  • significant gastroparesis
  • gastric outlet obstruction
  • ileus
  • known or suspected bowel obstruction or perforation
  • phenylketonuria
  • glucose-6-phosphate dehydrogenase deficiency
  • severe chronic renal failure (creatinine clearance <30 mL/minute)
  • severe congestive heart failure (NYHA class III or IV)
  • dehydration
  • severe acute inflammatory disease
  • compromised swallowing reflex or mental status
  • uncontrolled hypertension (systolic blood pressure ≥170 mm Hg, diastolic blood pressure ≥100 mm Hg)
  • toxic colitis or megacolon
  • previous colonoscopy within the last 5 years
  • active Inflammatory bowel disease
  • previous colectomy or partial colectomy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HallsPEG solution (Fortrans®) and Mentholyptus Drops (Halls®)every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
no HallsPEG solution (Fortrans®)Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
Primary Outcome Measures
NameTimeMethod
measurement of Palatability of the PEG-electrolyte solution1.5 hours after drinking the solution

patients will be asked to assess the palatability of the colon preparation solution (Fortrans®) by giving it a score on a scale from 1 to 5 with 1 being disgusting and 5 being tasty after drinking the whole solution and immediately prior to the colonoscopy

Secondary Outcome Measures
NameTimeMethod
volume remaining of the colon preparation solution1.5 hours after drinking the solution

Patients will be asked to bring with them to the endoscopy suit the volume remaining, if any, of the colon preparation solution that they were not able to drink. The volume remaining will be measured by the research fellow using a graduated cylinder.

Side effects1.5 hours after drinking the solution

number of patients who experienced nausea, vomiting, bloating, abdominal cramps or headaches while drinking the solution.

Trial Locations

Locations (1)

American University of Beirut Medical Center

🇱🇧

Beirut, Lebanon

© Copyright 2025. All Rights Reserved by MedPath